Future Value Creation Depends On Incorporating Data-Driven Technology, EY Concludes
Executive Summary
Biopharmas and other life sciences firms risk getting left behind by technology firms if they don't begin addressing patient needs more directly through data-driven technological advances, such as those to aid clinical development or treatment decisions with real-time patient data.
You may also be interested in...
Access To Widely Scattered Data A Major Challenge For Evolving Health Care Industry: EY Report
There is a tremendous opportunity to use available data to improve health care, EY concludes, but life sciences companies must contend with siloed information and access issues, as well as shifts in who holds the most valuable data.
Resilience Is Key For Medtechs Facing Provider And Payer Flux In 2018
Medtech firms entered 2018 knowing that demands from providers and payers are increasing, the pace of business is quickening, and at the same time patients are more empowered and market access routes are more exacting than ever. Against this backdrop, PwC explains the top health industry issues for the coming year, highlights the forces that will have the most impact on the industry in 2018 and explains why manufacturers need to be nimble.
FDA Approves First Digital Pill: Otsuka/Proteus' Abilify MyCite
Otsuka plans a slow, measured launch of Abilify MyCite, developed with Proteus Health. The product includes an ingested sensor that sends a signal to a wearable patch and an app that tracks ingestion, activity and mood to potentially improve management of psychiatric care.